Coty: Q1 earnings down sharply as expected, slightly more optimistic guidance for Q2|NIH attempts risky return to primary market|Sappi: EBITDA plummets in Q4 and the situation is unlikely to improve in the short term|Worldline presents its transformation plan and plans a capital increase of € 500m|Air Baltic: a new liquidity injection seems unavoidable|
Coty : Résultats T1 en net repli comme attendu, guidance légèrement plus optimiste pour le T2|NIH tente un retour risqué sur le marché primaire|Sappi : l’EBITDA s’effondre au T4 et la situation ne devrait pas s’arranger à court-terme|Worldline présente son plan de transformation et compte réaliser une augmentation de capital de 500 m EUR|Air Baltic: a new liquidity injection seems unavoidable|
Rdos. 3T'25 vs 3T'24: Ventas: 20.128 M euros (-2,3% vs -2,8% BS(e) y -2,6% consenso); EBIT: 1.477 M euros (+7,6% vs -7,6% BS(e) y -6,7% consenso); BDI: 840,0 M euros (+11,9% vs -5,9% BS(e) y -4,7% consenso). Rdos. 9meses'25 vs 9meses'24: Ventas: 60.763 M euros (-1,2% vs -1,4% BS(e) y -1,3% consenso); EBIT: 4.276 M euros (+5,9% vs +0,7% BS(e) y +1,0% consenso); BDI: 2.441 M euros (+9,1% vs +3,1% BS(e) y +3,5% consenso).
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.